News & Updates
Filter by Specialty:
Roflumilast shows treatment potential for seborrheic dermatitis
In the phase III STRATUM* trial, the investigational PDE4** inhibitor roflumilast improved multiple symptoms of moderate-to-severe seborrheic dermatitis (SD).
Roflumilast shows treatment potential for seborrheic dermatitis
15 Sep 2022
Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.
Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
14 Sep 2022
MRNA booster shot durably bolsters defenses against severe COVID-19
Boosting with an mRNA vaccine yields significant protection against severe COVID-19 and may keep people out of the hospital for up to 6 months, as shown in a Singapore study.
MRNA booster shot durably bolsters defenses against severe COVID-19
14 Sep 2022
Nicorandil improves PCI outcomes in STEMI patients
In patients with ST‐segment–elevation myocardial infarction (STEMI), treatment with nicorandil prior to undergoing primary percutaneous coronary intervention (PCI) may result in improved myocardial perfusion grade, increased left ventricular ejection fraction, and reduced myocardial infarct size, according to data from the CHANGE* study.
Nicorandil improves PCI outcomes in STEMI patients
14 Sep 2022
Ivermectin not superior to placebo in mild COVID-19
Early treatment with single- or double-dose ivermectin is no better than placebo in avoiding progression to hospitalization and in improving symptoms in mild COVID-19, results of a study have shown.
